

TOKYO
BIOTECH ENTREPRENEURSHIP
WORKSHOP

December 12
2023

In partnership with the U.S. Embassy Tokyo,
Japan Society of Northern California
and Ovibees Ventures



LOCATION

LINK-J Nihonbashi Life Science Building Room #201
2-3-11, Nihonbashi-honcho, Chuo-ku, Tokyo

Simultaneous interpretation in English and Japanese
英語と両方の同時解釈



A practical training and coaching event bringing together biotech ecosystem stakeholders for entrepreneurship skill building, fundraising pitching to U.S. and Japanese biotech investors and entrepreneurs.

PARTNERS



OUTREACH PARTNERS



AGENDA

13.00 – 13.30 Registration

13.15 – 13.40 Welcome remarks

Mr. Larry Greenwood, Board Chairman, Japan Society of Northern California

Mr. Alan Turley, Minister-Counselor for Commercial Affairs, U.S. Embassy, Tokyo

Mr. Takayuki Fujiyoshi, Deputy Secretary General for science, Technology and innovation Policy Deputy Secretary General, Office of Global Startup Campus Initiative, Cabinet Secretariat

Mr. Ovidiu Bujorean, CEO OviBees Ventures

13.40 – 13.55 Opening Keynote by Mr. Keita Mori-san, CEO of SAN-BIO Limited

13.55 – 14.10 Opening Keynote by Mr. Mitsuru Izumo-san, President, Euglena Co., Ltd.

14.10 – 15.00 Panel: “Japanese and U.S. biotech entrepreneurial ecosystems. Similarities, differences, and lessons learned along the way.”

Speakers:

Shinichiro Fuse, Partner/Managing Director at TPG Life Sciences Innovation

Taro Inaba, Founder/ Managing Partner at Remiges Ventures

Makoto (Mark) Otori, Chief Investment Officer at UTokyo Innovation Platform

Carolina Garcia Rizo, Partner, Evexia Fund

Fred Shane, Managing Partner, Axil Capital Partners – via Zoom

Christopher Ghadban, Principal, Alix Ventures, Founder 1Bio. (Moderator)

15.00 – 15.15 Networking Break

15.15 – 16.05 Training session: “Go to market strategies for biotech ventures.”

Carolina Garcia Rizo, Partner, Evexia Biofund

Christopher Ghadban, Principal, Alix Ventures, Founder 1Bio

16.05 – 16.20 Networking Break

16.20 – 17.10 Training session: “Fundraising best practices for biotech ventures.”

Christopher Ghadban, Principal, Alix Ventures, Founder 1Bio

Hiroki Sugita, Partner, Orrick, Herrington & Sutcliffe LLP

17.10 – 17.20 Networking Break / Preparation for pitching

17.20 – 18.20 Elevator Pitch: Japan-based Entrepreneurs 90-second pitch to a panel of U.S. and Japanese investor and seasoned entrepreneurs.

Judges:

Taro Inaba, Founder/ Managing Partner at Remiges Ventures

Makoto (Mark) Otori, Chief Investment Officer at UTokyo Innovation Platform

Shinichiro Fuse, Partner/Managing Director at TPG Life Sciences Innovation

Carolina Garcia Rizo, Partner, Evexia Fund

Takaaki Ishii, Investment Director, Taiho Ventures

Takashi Futami, Life Science Venture Capitalist, AN Venture Partners

Christopher Ghadban, Principal, Alix Ventures, Founder 1Bio

Ayodele Alaran, OviBees Ventures, Moderator

18.20 – 18.40 Networking Break

18.40 – 18.50 Announcement of the Top 5 winners.

Ayodele Alaran, OviBees Ventures

18.50 – 19.00 BioJent Next Steps. Closing Remarks.

Mr. Ovidiu Bujorean, CEO OviBees Ventures

Mr. Larry Greenwood, Board Chairman, Japan Society of Northern California



Mr. Takayuki Fujiyoshi

Mr. Takayuki Fujiyoshi, Deputy Secretary General for science, Technology and innovation Policy. Deputy Secretary General, Office of Global Startup Campus Initiative, Cabinet Secretariat.

Academic Career

- 1992 Bachelor of Engineering, Department of Technology, Tohoku University, Japan
- 1994 Master of Engineering, School of Engineering, Tohoku University, Japan
- 2000 Master of Arts in Law and Diplomacy, Fletcher School of Law and Diplomacy, Tufts University, USA

Professional Career

- 1994 Science and Technology Agency (STA), Government of Japan
- 1996 Chief, Coordination Division, Science and Technology Policy Bureau, STA
- 2000 Deputy Director, Learning and Information Division, Life-long Learning Bureau, Ministry of Education
- 2002 Director, General Affairs Division, Kyushu University
- 2005 Deputy Director, General Affairs Division, Council of Science and Technology Policy, Cabinet Office
- 2007 First Secretary (Science Attache), Embassy of Japan in France
- 2010 Director, Quantum Radiation Research Office, Research Promotion Bureau, Ministry of Education, Culture, Sports, Science and Technology (MEXT)
- 2011 Secretary to the Minister of MEXT
- 2012 Director for Nuclear Damage Compensation Division, MEXT
- 2014 Director for Human Resources Division, Ministers Secretariat Bureau, MEXT
- 2016 Director, Environment and Energy Division, Research and Development Bureau, MEXT
- 2018 Director, Space Development and Utilization Division, Research and Development Bureau, MEXT
- 2021 Director, Student Division, Higher Education Policy Bureau, MEXT
- 2023 Deputy Director General for Science, Technology and Innovation Policy, Cabinet Office



Shinichiro Fuse

Partner/Managing Director at TPG Life Sciences Innovation

Dr. Shinichiro (Shin) Fuse, is Partner and Managing Director at TPG Life Sciences Innovation. He co-leads life sciences venture investments at TPG and serves on the Board of Directors at Santa Ana Bio. Previously, he was Managing Director at MPM Capital, where he served on the investment committee of the Oncology Impact Fund (OIF) and BioVentures Funds. Shin served on the Board of Directors of Orna Therapeutics, iOmx Therapeutics, Triplet Therapeutics and ReNAGade Therapeutics, and as a board observer for ElevateBio and Repare Therapeutics. Shin also played operational roles at MPM portfolio companies as the interim CEO of Orna Therapeutics and interim/founding SVP of Business Development at ElevateBio.

Prior to joining MPM, he was Director of Business Development at bluebird bio, where he was instrumental in executing and managing key industry and academic partnerships in the fields of cell and gene therapy, cancer immunotherapy and genome editing. Previously, he was at Campbell Alliance (Syneos Health) as a life science strategy consultant, and an associate at PureTech. He currently serves on the Board of Advisors of the Guarini School of Graduate and Advanced Studies at Dartmouth College. He also served as a part-time columnist for Nikkei Biotech, writing on trends in the US biotech sector.

Shin received his Ph.D. in Microbiology and Immunology from Dartmouth College, an M.S. in Biomedical Science from the University of Tokyo, and a B.Eng. in Applied Chemistry from Keio University in Japan.



Takashi Futami

Life Science Venture Capitalist at AN Venture Partners

Dr. Futami is an experienced healthcare investor, entrepreneur and executive. He started his career as a researcher at Astellas Pharma Inc. where he led and managed more than 10 drug discovery projects, mainly in oncology and metabolic disorders.

He subsequently joined Astellas's corporate venture capital arm in Menlo Park and Cambridge and was involved in many successful investments, including Potenza Therapeutics (acquired by Astellas), Bicycle Therapeutics (IPO: NASDAQ). He also managed collaborations with top academic institutes, including Dana-Farber cancer institute, Massachusetts General Hospital, and Weill Cornell Medicine.

Most recently, Dr. Futami was a Principal at Fast Track Initiative and played a key role in global investments and company creation from academic discoveries by identifying and evaluating new life sciences technologies. He is co-founder of reverSASP Therapeutics, K.K., a venture-backed biotech start-up based on Japanese academic discoveries.



Christopher Ghadban

Principal, ALIX Partners, Manager BIOS

Christopher Ghadban is an entrepreneur & venture capitalist passionate about supporting frontier technologies to create a healthier and more equitable future.

Chris currently serves as a Principal at Alix Ventures, where he supports high potential, early-stage life science start-ups harnessing the power of biology to drive radical advances in human health. He also manages BIOS, Alix's media platform, and is the Founder of 1bio, which brings together thousands of individuals across the life sciences in over a dozen cities through a series of initiatives including community events and mentorship programs.

Prior to joining Alix, Chris was a Strategy & Innovation Program Lead with AstraZeneca's Emerging Innovations Unit – combining BD, S&E, and innovation strategy. Before AstraZeneca, Chris founded a boutique startup consultancy where he advised over a dozen promising biotechnology companies. Chris earned his undergraduate & graduate degrees @ Tufts University, where he completed his MS in Bioengineering and BS in Chemical Engineering & Biotechnology Engineering. Chris also earned his MBA @ Wharton (University of Pennsylvania) with a focus in Healthcare Management.

In his spare time Chris can be found outdoors, making new recipes, exploring used bookstores, filling his sketchbook, learning to salsa dance, and advising new ventures – Mentoring @ iGEM, Nucleate, MassBio, and more. Reach out to Chris@alix.vc to get in touch!



Carolina Garcia Rizo

Partner, Evexia Biofund

Dr. Garcia Rizo is a global multilingual business developer that leverages her scientific experience and technology/ML/AI expertise to create the highest value for customers and drive sustainable growth in Healthcare, Biotech, and Diagnostics.

She is an energizing global leader of cross-functional teams worldwide with an extensive network across VC's, Biotech, Big Pharma, Providers, Payers, and Regulatory Agencies. She is a mentor, thought leader, and a frequent speaker at ML-Biotech conferences, financial and industry events.

Carolina is passionate about leveraging ML to improve the efficiency and speed of drug discovery and development. She has been a Chief Business Officer of several biotechs growing their business, increasing profitability and leading to successful exits (Sell & IPO). Currently she is in the board of several startups and does BD consulting for some biotechs.

Dr. Garcia Rizo has a MBA from MIT and a PhD in Atomic and Molecular Physics performed at CSIC, CNRS and UC Berkeley, where she was a Fulbright Scholar.



Taro Inaba

Founder and Managing Partner at Remiges Ventures at Remiges Ventures

Taro Inaba is Founder and Managing Partner at Remiges Ventures. He has over 32 years of business experience including 22 years in start-up financing and company creation in the life science area. At Remiges, Taro is engaged in technology sourcing, company creation, and serving as director for multiple companies for the Remiges' portfolio including Inflectis Bioscience, Omeicos Therapeutics, Imel Biotherapeutics, Luca Science and Capacity Bio. Above all, he is fascinated with and loves mitochondrial science and is working with researchers, scientists, physicians, and patient advocacy groups in the field. Prior to Remiges, Taro was Head of the Corporate VC and other divisions at Mitsui & Co. a large Japanese company including a position as President & CEO at Mitsui & Co. Venture Partners in Menlo Park, CA, where he built and managed a biopharmaceutical investment team and portfolio that delivered excellent financial performance. Taro holds a B.E. in Polymer Chemistry, Kyoto University and MBA from European University.



Takaaki Ishii

Investment Director – Taiho Ventures, LLC.

Takaaki Ishii, a molecular biologist by training, joined Taiho Ventures in 2019. He has acquired over 11 years of oncology expertise in early stage clinical development, product portfolio strategies as well as scientific evaluations for in-house and potential partnering programs in a wide range of cancer types.

His representative contribution to Taiho Pharmaceutical includes in-licensing AB928 (A2aR/A2bR Dual Antagonist) from Arcus Biosciences as well as both medical and Medical Science Liaison activities for nab-paclitaxel (ABRAXANE®) and pembrolizumab (KEYTRUDA®) in Japan.





Mitsuru Izumo

President, Euglena Co., Ltd.

Mitsuru Izumo is a graduate of the University of Tokyo, having specialised in agricultural structural management. In 2005, he established Euglena Co., Ltd. to harness the properties of microalgae Euglena. Euglena Co., Ltd. became the world's first biotechnology company that succeeded in the outdoor mass cultivation of Euglena. Currently, Euglena Co., Ltd. upholds "Sustainability First" as their philosophy and has developed the manufacture and sale of foods and cosmetics as the healthcare domain, the biofuel business, the bioinformatics business, and the social business in Bangladesh by leveraging Euglena and other advanced technologies.



Keita Mori

CEO, SanBio Co., Ltd.

Mr. Mori has been Chief Executive Officer and has served as a member of the Board since SanBio's inception in 2001. Prior to founding SanBio, Mr. Mori was Head of New Product Development from 2000 to 2001 at Xuma, an informatics startup in San Francisco. From 1993 to 1999, Mr. Mori held positions of increasing responsibility in R&D and Manufacturing at Kirin Holdings, Ltd. in Japan.

Mr. Mori holds an MBA degree from the University of California, Berkeley and a master's degree in Biochemistry from the University of Tokyo.



Makoto (Mark) Ohori

Chief Investment Officer at UTokyo Innovation Platform Co. (UTokyo IPC)

Dr. Makoto (Mark) Ohori is Partner and Chief Investment Officer at UTokyo Innovation Platform Co., Ltd. (UTokyo IPC). In this role, he spearheads the life sciences investments at UTokyo IPC. Dr. Ohori also serves on the Board of Directors at Axial Therapeutics (Woburn, MA), reverSASP Therapeutics Inc. (Bunkyo, Tokyo), Heartseed Inc. (Minato, Tokyo), LiberoThera Inc., and RIN Institute (Chuo, Tokyo), and as a Board Observer for DEM Biopharma (Cambridge, MA), Carbon Biosciences (Waltham, MA), and STORM Therapeutics (Cambridge, UK). Additionally, at reverSASP Therapeutics, he serves as the Representative Director and Board Chair, directly managing the startup's operations and strategic direction.

Prior to joining UTokyo IPC, Dr. Ohori was the Executive Director and Head of Early-stage Partnering at Astellas Innovation Management in Cambridge, MA. There, he managed a global business development team for innovation acquisition and established strategic partnerships with biopharmaceutical companies and academic institutions, such as Pandion Therapeutics, Harvard University, MIT and Boston Children's Hospital. In these partnerships, Dr. Ohori played a pivotal role such as a member of the Joint Steering Committees, overseeing collaborative efforts and guiding strategic decisions.

Earlier in his career, Dr. Ohori was an Investment Director at Astellas Venture Management in Menlo Park, CA, where he invested in a range of promising biotech startups including Verastem, Fate, Cleave, Epizyme, PhaseBio, eFFECTOR, Crescendo (UK), Bicycle Therapeutics, Mitobridge, and Tizona.

As part of his responsibilities there, Mark led build-to-buy company creations at Astellas, such as Potenza Therapeutics in Cambridge, which was successfully acquired by Astellas in 2019.

Mark has over 20 years of experience as a drug discovery scientist in both the small molecule and biologics fields. He received his Ph.D., M.S., and B.S. in Pharmaceutical Sciences from the University of Tokyo in Japan.



Jim Roberts

Technology Licensing Officer, Biotech, Massachusetts Institute of Technology Technology Licensing Office

At Massachusetts Institute of Technology (MIT), Jim Roberts evaluates and protects new inventions in life sciences from principal investigators and their labs, for commercial and societal impact. Building on a portfolio of impactful inventions, Jim Roberts facilitates the translation of these technologies into commercial products and services all over the world using the mechanisms of licensing and company creation on behalf of MIT and to the benefit of the Institute, its inventors, licensees, and the public at large.

Before joining the Massachusetts Institute of Technology Technology Licensing Office (MIT TLO), Jim Roberts was the Director of Licensing at CU Innovations, where he led a team of 6 licensing managers. Together they provided research, licensing, and company creation support to principal investigators at CU's Anschutz Medical and Denver campuses.

Prior to CU Innovations, Jim Roberts was the Associate Director at Partners Healthcare Innovations and previously held various patent sourcing and monetization positions at Conversant IP Management, Rembrandt IP Management, Real Clear Intelligence, and BTG International, where he led a global team of 12 technology acquisition executives.



Jim Roberts has worked in medicine as a medical physicist in four different hospitals and held various marketing and sales positions at Philips Healthcare.

His skills include patent sales, patent acquisitions, patent licensing, patent enforcement, technology and patent assessment, organizational leadership, global team management, alliance management, business development, product sales, product marketing, technical marketing, and competitive intelligence.

Jim Roberts' goal is to facilitate the smooth transaction of valuable technology for the furtherance of meaningful research aims and impactful products.



Fred Shane

Managing Partner, Axil Capital Partners

Fred is a seasoned investment professional with over 20 years of experience in the VC, PE, and investment banking industries, where he has assumed a number of key positions at multiple prominent organizations.

Early in his career, Fred was instrumental in setting up the biotech investment team within the Investment Business Dept of Marubeni USA, where he gained deep experience in sourcing, evaluating, executing and actively supporting young biotech startups through successful exits. Subsequently, Fred joined Patriarch Partners, a distressed private equity firm, where he was rapidly promoted to the Co-Head of Credit Team position and continued to manage a team of 14 investment professionals overseeing hundreds of distressed and high yield credits across five funds totaling multi-billion dollars in AUM.

Most recently, Fred served Mizuho Securities, a Japanese investment bank, as a VP in the ECM Dept and subsequently as a Director in the Investment Business Department, from where he successfully launched Axil Capital, a life sciences VC firm, in August, 2017. Fred holds a B.S. degree in Electrical Engineering & Computer Science from M.I.T. He is a native and technical-level bilingual in Japanese and English, and is proficient in multiple scientific disciplines.



Hiroki Sugita

Orrick, Herrington & Sutcliffe LLP

Hiroki Sugita is a partner in Orrick's Tokyo Office and a member of the M&A and Private Equity Group. He works on a wide range of cross-border transactions including mergers and acquisitions, joint ventures, emerging companies and venture capital transactions, and private equity investment especially in Japan, the United States, Europe and Asia.

Hiroki has extensive experience in the healthcare and life science industries, including biotechnology, pharmaceuticals, digital health, research, laboratories, medical devices, and diagnostic tools, providing valuable advice and solutions to his clients.



Mr. Alan Turley

Minister-Counselor for Commercial Affairs, U.S. Embassy, Tokyo

Alan Turley is the Minister-Counselor for Commercial Affairs at the U.S. Embassy in Tokyo, Japan. He leads a team of 36 U.S. Commercial Service professionals in Tokyo and Osaka that is dedicated to promoting closer trade and economic ties between the United States and Japan. The CS Japan team promotes U.S. exports to Japan, encourages Japanese direct investment into the United States, works to improve the trade and investment climate in Japan and advises the leadership in the Department of Commerce on trade-policy issues regarding the bilateral commercial relationship.

Prior returning to Tokyo, Mr. Turley was the Deputy Assistant Secretary of Commerce for China and Mongolia in Washington D.C., where he was responsible for International Trade Administration (ITA) programs in those markets. From 2002 to 2016, Mr. Turley was Vice President for International Affairs in Asia Pacific for FedEx Express. Twice a winner of FedEx's coveted "Five Star Award", Mr. Turley helped manage FedEx's rapid growth and expansion in Asia, including the building of China's first international air express hub, the founding of FedEx's wholly-owned operations in China, and the approval of FedEx's purchase of TNT Express.

Mr. Turley's previous service in the U.S. & Foreign Commercial Service started in 1986 in Japan, where he headed the Major Projects and Transportation Equipment Unit. Mr. Turley then served as the Director of the Commercial Service's International Marketing Center at the U.S. Embassy in London before moving back to Asia to become Deputy Senior Commercial Officer at the American Institute in Taiwan. From 1996 to 2000, Mr. Turley was the Minister-Counselor for Commercial Affairs at the U.S. Embassy in Beijing and after that service he returned to Japan to serve in the same capacity at the U.S. Embassy in Tokyo.

Alan Turley was educated in public schools in Cheshire Connecticut and was graduated from the University of Virginia with High Honors in 1983. After receiving his B.A., Mr. Turley spent two years studying Chinese in Taiwan at National Taiwan Normal University's Mandarin Training Center.



OUTREACH PARTNERS



Brandon Possin

Brandon Possin has served his country as an American diplomat for 17 years, currently serving as political-economic section chief at the U.S. Consulate in Fukuoka. Previously, he bridged U.S. and Japanese scientific and health communities as economic officer at U.S. Embassy Tokyo. Previously, he worked to restore democracy to Venezuela at the Venezuela Affairs Unit based temporarily in Bogota, Colombia. He earlier served as Political/Economic Section Chief at the U.S. Consulate General in Surabaya, Indonesia. Additionally, he helped build Pakistan's first incubator for women entrepreneurs while at U.S. Embassy Islamabad (Pakistan). Other assignments included advising trade negotiations and Asia Pacific Economic Cooperation as Economic Officer at the U.S. Embassy in Lima (Peru), as Consular Officer/Ambassador Aide at the U.S. Embassy in Jakarta (Indonesia), and as intern in the environmental section of the U.S. Embassy in Buenos Aires (Argentina). He is a native of Verona, Wisconsin, graduated with honors from the University of Virginia, and studied abroad at universities in Chile and Brazil. Brandon speaks Portuguese, Indonesian, Spanish, conversational Japanese, and basic Urdu.



ORGANIZERS



Ovidiu Bujorean
CEO, OviBees Ventures

Ovidiu Bujorean, a MIT and Harvard alumni and scholar of the Joint Japan/World Bank Graduate Scholarship Program, the founder of OviBees Ventures, is a leader in designing and implementing platforms that encourage technology-based entrepreneurship at country and regional levels. His previous work with The GIST Network, the U.S. Department of State flagship entrepreneurship program, a global enterprise building entrepreneurial ecosystems across 135 countries, showcased his dedication to fostering entrepreneurship on a global scale.



Ayo Alaran
OviBees Ventures

Ayo is Chief Operating Officer at DelNovak LLC. DelNovak is a government contractor, with expertise in Cyber Security and Technology Transformation. At DeNovak, Ayo is responsible for business development, client delivery, partnerships, internal operations, and capture management.

Ayo is an entrepreneur (started over 5 companies), investor, and higher performance professional with over 20 years of Technology, Business Operations, Project Management, and contributions to government agencies. Ayo's expertise includes Project Management, Cyber Security Hygiene, Emerging Technologies, Digital Transformation, and Business Process Transformation.

Ayo's experience includes contributions at government agencies such as the Centers for Disease Control and Prevention, Department of Defense (Army, Marines), USAID, Transit Agencies, and local governments. Ayo continuously exceeds client expectations by focusing on operational excellence and strong program delivery.

Ayo volunteers to propagate mindfulness to humanity. As a member of the Working Group Leadership and Faculty Member at the Herndon Directors Institute (HDI), Ayo supports HDI in its mission to educate and to increase minority and women participation on corporate boards.

Ayo is a regular financial supporter to various charitable causes and holds a PMP certification and degrees from Georgia Tech and MIT.



Miyako Takase
OviBees Ventures

- AIESEC Japan
- Studied at the boarding school in the UK
- Joined Parents and Teen Program of Harvard Business School
- Participating Internship at Svenskt Tenn in Sweden
- Marketing and Researching Market with Svenskt Tenn
- Hard Working at a Tennis club in a junior high school
- Playing Golf in the University
- Participating Internship at a company about immigrants in Japan
- Studying Economics around the world at the university
- Studying about immigration issues at the university and internship





Larry Greenwood

Board Chairman, Japan Society of Northern California

Larry Greenwood is senior adviser to the BowerGroupAsia, a government-relations consulting firm in Washington D.C. He lives and works in the San Francisco Bay Area. He was president of the Japan Society of Northern California until stepping down at the end of 2019.

Greenwood worked four years in Tokyo, where he managed government relations throughout Asia for MetLife, and for five years in Manila, Philippines, where he co-led the Asian Development Bank and was responsible for about \$7 billion of development lending a year.

From 1976-2006 he served as a U.S. diplomat in overseas assignments at the embassies in Tokyo, the Philippines and Singapore and in a variety of other jobs at the State Department, including as ambassador to the Asia Pacific Economic Cooperation (APEC) group and principal deputy assistant secretary for economic and business affairs. Greenwood is a non-resident senior associate at the Center for Strategic and International Studies, one of the most prominent think tanks on international issues in Washington D.C. He serves on the boards of the Japan Society of Northern California and Capital Sisters, a non-profit that funds micro-loans for poor women in emerging economies.

He holds a BA from Eckerd College in St. Petersburg, FL, and an MALD from the Fletcher School of Law and Diplomacy in Medford, MA. He speaks and reads English, Japanese and French. Solecatur, totatibus.



Steve Pollock

President, Japan Society of Northern California

Steve Pollock serves as President of the Japan Society of Northern California (JSNC), a position he has held since 2022. Steve has been a member of the JSNC Board of Directors of since 2015. From 2015-2020, he was a member of the Executive Committee and Chair of the Sponsorship Committee. He has been an active member of the Steering Committee for the Innovation Awards, and also initiated and led JSNC's activities in Japan while living in Tokyo from 2016-2018.

Steve began his career at Mitsubishi International Corporation, where he worked in the Heavy Machinery Division in New York. Later, he co-founded and was president of WetFeet, a venture-backed software and services startup in the recruiting space. After WetFeet was acquired, he founded Turnstone Ventures, a boutique consulting firm that provided strategic advice and market entry support to numerous companies in the US and Japan. In addition to the Japan Society, Steve co-teaches a course on entrepreneurship at Waseda University, and serves on the Board of Ocean Outcomes, an environmental nonprofit focused on sustainable seafood.

Steve received a BA degree, summa cum laude, in East Asian studies from Harvard College, and an MBA from the Stanford Graduate School of Business. Steve studied, lived and worked in Japan for many years and speaks, reads and writes Japanese.



Takahide Akiyama

Takahide Akiyama is a trusted and experienced international business leader and has held a number of senior management positions of major global companies including Japan Country Head of the Bank of New York, President and CEO of Bank of New York Securities Japan, President and CEO of CBRE K.K. and prior to these positions, he was Head of Global Project Finance of the Industrial Bank of Japan. More recently, he was a Board Managing Director of erex Co. Ltd., (TSE Prime listed) as well as President and CEO of its US-Japan joint venture company in Japan's newly deregulated market until 2019.

Between 2020 and 2023, he was President and Board Director of Japan Society of Northern California. He currently serves as its Board Vice Chair.

He holds MA and BA degrees in politics, philosophy and economics (PP&E) from Oxford University and BA degree in economics from Keio University in Japan.

HealthTech, Inc. <http://www.linkedin.com/in/annatee>

We are working on a patient/caregiver-centric mobile health platform to enable multiple stakeholders to collaborate on the care of the patient seamlessly, with initial focus on senior care. We are in the prototyping stage, currently looking for users to collaborate and provide feedback. I have learned about your event after booking my trip from CA to Hong Kong, with a brief stop in Tokyo, so I could attend the latter part of the event, as the flight is scheduled to arrive after the start of the event.

Rhea's Factory www.rheasfactory.com

Rhea's Factory is leveraging innovative enzymatic technology to combat the global plastic waste crisis. Our unique approach efficiently converts all types of plastic waste into high-quality materials, tapping into previously overlooked mixed plastic waste streams as valuable feedstocks. Our cutting-edge solution reduces dependency on fossil fuels and effectively recycles the previously deemed 'un-recyclable,' potentially eliminating 6 billion tons of legacy waste.

ekei labs www.ekeilabs.com

I am the first founder sponsored by Shibuya City within their startup support program. We are funded by a Japanese VC and are doing joint research with OIST. We develop biological age measurement methods.

ORBIO Corporation www.orbio.jp

ORBIO Corporation discovered that only cancer cells intake L-Glucose a decade ago. Since then, we have developed a unique and paradigm-disruptive modality using L-Glucose-based drugs consisting of cancer biomarkers and anti-cancer agents. We have already tested the biomarker in pilot studies using clinical specimens of various types of cancers. We also got significant outcomes from animal testing of the therapeutic agent. The founders of ORBIO are top scientists from Kyoto University and Hirosaki University, top universities in Japan. We are currently seeking for capital to commercialize this modality.

Eurotechnology Japan KK <https://eurotechnology.com/>

firm: building Japan business for foreign cell therapy/venture developing immune system therapies and medical device firms. self: PhD Physics (Cambridge Univ UK), working in Tokyo since 1991 in high tech and pharma business, M&A and bus dev

Ruten, Inc. www.ruten-neuro.com

Ruten is a Brain-Machine Interface company aiming to establish reconstructive treatments for conditions where standard options are either infeasible or ineffective.

Dioseve, Inc. <https://dioseve.com/en/home-en/>

We are a biotech venture focused on developing the technology to turn skin cells into viable egg cells. Not only can it produce a large number of eggs in a short amount of time and at a much lower cost than conventional methods. Uses of such technology includes but is not limited to groundbreaking infertility treatment methods, and it even opens avenues for treating numerous number of genetic diseases. The invention was published in Nature(<https://www.nature.com/articles/s41586-020-3027-9>).

Physiologas Technologies, Inc. <https://physiologas.co.jp/>

Developing "hemodialysis device" for treatment at home.

xFOREST Therapeutics <https://www.xforestx.com/>

I am a Chief Strategy Officer at xFOREST Therapeutics. xFOREST Therapeutics aims to create a paradigm shift in drug discovery with its unique technological assets "FOREST", setting RNA structures as drug discovery targets. FOREST are technology platforms that integrate massively parallel biochemical analysis systems of 1,000~ species of RNA structures and in silico analysis pipelines. These comprehensive analyses include various RNA structures, regardless of their source: organ, species, or virus. As a result, the technologies have enabled the search for highly specific RNA-binders, empowering the rapid and efficient discovery of RNA-targeting drugs.

FELIQS <https://feliqs.com/>

"FELIQS is a preclinical stage Japanese company. The Company has a portfolio of two patent protected drug product ophthalmology candidates:

- Age-related macular degeneration (AMD) ,Ài FLQ-104, a proprietary lipid peroxidation and ferroptosis inhibitor for earlier intervention to treat AMD. FLQ-104 is currently in discovery stage in Japan and in US.
- Retinopathy of prematurity (ROP) ,Ài FLQ-101, a lipid peroxidation inhibitor repurposed to prevent ROP. FLQ-101 will be in Phase I/II dosing planned in the US for 2024.

- Each of these developmental candidates is identified through FELIQS,Às proprietary screening platform targeting lipid peroxidation/ferroptosis with proven efficacy from past prospective clinical trials.

- Each developmental candidate offers an attractive value proposition in terms of safety and convenient route of administration (oral). FELIQS is currently advancing its pipelines to clinical development with well-experienced academic and industrial advisors.

- FELIQS is initiating a Series A round targeting \$10 million to initiate a clinical trial for ROP(FLQ-101), and preclinical research for FLQ-104. For this expansion of the future product portfolio and to prepare for a successful future M&A or IPO, FELIQS is looking for investors and partners to participate in the opportunity of this new and proprietary technology."

I Peace, Inc. <https://ipeace.com/en/>

We are a Palo Alto-based biotech startup specializing in iPS cells, and our CEO, Dr. Tanabe, is the second author of the world's first paper on human iPS cell (induced pluripotent stem cell) paper for which he won the Nobel Prize (CV attached). We are engaged in iPS cell production for pharmaceutical companies and cell therapy companies, and also provide iPS cell banking services for individuals. We envision a world where every individual possesses their own iPSCs, securely banked for future use if the need arises.

Provigate, Inc. <https://provigate.com/en/>

Provigate provides the world,Às first painless and accurate glycated albumin monitoring service, glucreview→Æ. It,Às once-a-week, affordable, and motivating. We unlock the power of behaviour change.

United Immunity <https://unitedimmunity.co.jp/eng/>

Biotech company with myeloid-cells targeting nanoparticle platform. Lead program in the cold tumor treatment area.

Onco Decision

Our mission is to make cancer a manageable disease by developing a machine learning algorithm that generates multiomics, co-alteration signatures recurrent within a cancer patient cohort. These signatures can inform combination therapies for patients and provide valuable input for clinical trial design for pharma companies.

BB Medical Surgical, Inc. www.bbmedicalsurgical.com

We are developing a low-cost airway management device to allow first responders, nurses, pediatricians, and even laypeople to save lives by keeping the airway open.

BioPhenoMA, Inc. <https://www.biophenoma.com>

Providing high-sensitivity quantification services for ultra-trace proteins, we will develop untapped biomarker or measurement method to support research and development of pharmaceuticals, quasi-drugs, reagents, etc.

Tupac Bio, Inc. www.genomeminer.ai

CFO of a bioinformatics genome mining start up

Posh Wellness Laboratory, Inc <https://posh-wl.co.jp>

To save as many people as possible using novel technology, our company has been established since 2015. We proposed new wearable technologies such as E-Textile technology and electrode contactless impedance measurement for detecting health anomalies in daily life. Our concept of technology is integrating sensors into daily necessities such as cloths, ID card that would be carried every day. The technologies have been used for Seat Belt Sensors, Seat Cover Sensors, Smart Health ID Card, Nappy Sensors, Liquid Leakage Sensors, Sleep Apnea Sensors, and Radiation-free Tomographic Devices etc. Therefore, those technologies would be used for a variety of applications. The technology of Seat Belt Sensor won the 2019 Edison Awards.

S & K Biopharma, Inc. <https://skagayasandk.wixsite.com/>

Our business is the development of multi-functional protein lactoferrin drugs for infections and neurological diseases. Since wild-type lactoferrin is not stable in the blood, we are producing novel lactoferrin drugs that fusion human IgG FC region or human serum albumin.

MediGear International <http://www.medigear.co.jp/>

We are a startup team developing an unique drug free cancer therapy for patients who have no therapeutic options left, as a tiny biodegradable medical device (class III) shutting off O2 and nutrient from tumor. This technology has been patent granted in Japan and EU, under exam in the US. We hope to execute this business in the US first.

A mother raising a down syndrome boy in Japan. Chinese, Product Manager, Engineer, Chinese.

NERON, Inc. <https://neron.jp>

Microbiome Formulation Contributing to Mental Health and Well-being

CUBICStars, Inc. <https://www.cubicstars.com>

A Startup in Biology and Digital Technology originating from the University of Tokyo and RIKEN.

We provide preclinical drug discovery support services to pharmaceutical industry scientists using our whole organ 3D imaging technology at the cellular level.

FerroptoCure, Inc. <https://ferroptocure.com>

"FerroptoCure Inc, is established in May 2022 and a company that develops next-generation anticancer drugs and other therapeutic drugs based on the findings in Keio university. We focus on ferroptosis. We raised \$ 4.5 million in May 2023 and are developing world 1st Ferroptosis inducing anti-cancer therapy. AS in any cell type, cancer cells depend on the regulation system of ferroptosis. Therefore, our drugs can induce cancer cell death strongly and widely.

We are going to start Phase 1 study (First in Human) in Q1 2024."



BIOJENT JUDGES



Taro Inaba

Founder/ Managing Partner at
Remiges Ventures



Makoto (Mark) Ohori

Chief Investment Officer
at UTokyo Innovation Platform



Shinichiro Fuse

Partner/Managing Director
at TPG Life Sciences Innovation



Carolina Garcia Rizo

Partner, Evexia Fund



Takaaki Ishii

Investment Director, Taiho Ventures



Christopher Ghadban

Principal, Alix Ventures, Founder 1Bio



Takashi Futami

Life Science Venture Capitalist,
AN Venture Partners



Keita Mori

CEO, SanBio Co., Ltd.



Ayodele Alaran

OviBees Ventures, Moderator

BIOJENT MENTORS



Shinichiro Fuse

Partner/Managing Director at TPG Life Sciences Innovation

Dr. Shinichiro (Shin) Fuse, is Partner and Managing Director at TPG Life Sciences Innovation. He co-leads life sciences venture investments at TPG and serves on the Board of Directors at Santa Ana Bio. Previously, he was Managing Director at MPM Capital, where he served on the investment committee of the Oncology Impact Fund (OIF) and BioVentures Funds. Shin served on the Board of Directors of Orna Therapeutics, iOmx Therapeutics, Triplet Therapeutics and ReNAGade Therapeutics, and as a board observer for ElevateBio and Repare Therapeutics. Shin also played operational roles at MPM portfolio companies as the interim CEO of Orna Therapeutics and interim/founding SVP of Business Development at ElevateBio.



Carolina Garcia Rizo

Partner, Evexia Biofund

Dr. Garcia Rizo is a global multilingual business developer that leverages her scientific experience and technology/ML/AI expertise to create the highest value for customers and drive sustainable growth in Healthcare, Biotech, and Diagnostics.

She is an energizing global leader of cross-functional teams worldwide with an extensive network across VC's, Biotech, Big Pharma, Providers, Payers, and Regulatory Agencies. She is a mentor, thought leader, and a frequent speaker at ML-Biotech conferences, financial and industry events.



Christopher Ghadban

Principal, Alix Ventures; Founder, 1bio

Christopher Ghadban is an entrepreneur & venture capitalist passionate about supporting frontier technologies to create a healthier and more equitable future.

Chris currently serves as a Principal at Alix Ventures, where he supports high potential, early-stage life science startups harnessing the power of biology to drive radical advances in human health. He also manages BIOS, Alix's media platform, and is the Founder of 1bio, which brings together thousands of individuals across the life sciences in over a dozen cities through a series of initiatives including community events and mentorship programs.

In his spare time Chris can be found outdoors, making new recipes, exploring used bookstores, filling his sketchbook, learning to salsa dance, and advising new ventures – Mentoring @ iGEM, Nucleate, MassBio, and more. Reach out to Chris@alix.vc to get in touch!



Michael Koeris

Chairman of the Board of Directors, Corvium

Dr. Michael Koeris serves as Professor of Bioprocessing and is a member of the Amgen Bioprocessing Center in the Department of Biological Engineering and Management. Prior to joining KGI in 2021, Koeris actively started, grew, and exited biotech startups, both as founder and senior leadership member and Board of Directors.

Koeris' research and teaching focus on all aspects of CMC for microbiome medicines (bacteria, bacteriophages, and combinations thereof) as well as advanced cell and gene therapy (ACGT) approaches. He principally teaches the curriculum for Master of Engineering in Biopharmaceutical Processing students but overlaps with Master of Business and Science students.

Koeris holds a PhD in Biomedical Engineering from Boston University and Masters and Bachelors degrees in Biochemistry and Biophysics from the Free University of Berlin, Germany.



Fred Shane

Managing Partner, Axil Capital Partners

Fred is a seasoned investment professional with over 20 years of experience in the VC, PE, and investment banking industries, where he has assumed a number of key positions at multiple prominent organizations.

Early in his career, Fred was instrumental in setting up the biotech investment team within the Investment Business Dept of Marubeni USA, where he gained deep experience in sourcing, evaluating, executing and actively supporting young biotech startups through successful exits. Subsequently, Fred joined Patriarch Partners, a distressed private equity firm, where he was rapidly promoted to the Co-Head of Credit Team position and continued to managed a team of 14 investment professionals overseeing hundreds of distressed and high yield credits across five funds totaling multi-billion dollars in AUM.



Hiroki Sugita

Orrick, Herrington & Sutcliffe LLP

Hiroki Sugita is a partner in Orrick's Tokyo Office and a member of the M&A and Private Equity Group. He works on a wide range of cross-border transactions including mergers and acquisitions, joint ventures, emerging companies and venture capital transactions, and private equity investment especially in Japan, the United States, Europe and Asia.

Hiroki has extensive experience in the healthcare and life science industries, including biotechnology, pharmaceuticals, digital health, research, laboratories, medical devices, and diagnostic tools, providing valuable advice and solutions to his clients.

BIOJENT TOP 5 BIOTECH VENTURES

Physiologas Technologies Inc.

Industry: Pharmaceutical and Medical Device Manufacturing

Purpose: Improve the well-being of patients and their family through innovation in medical care using technology.

- Values:**
1. Think different.
 2. Work together.
 3. Drive with agility.
 4. Behave with integrity.



physiologas.co.jp

I Peace, Inc.

Happier, healthier life with iPSC technology

I Peace's mission is to alleviate the suffering of diseased patients and help healthy people maintain a high quality of life. Our goal is to create iPSCs – a type of stem cell – for every individual that becomes his/her stem cells for life. At I Peace, we are taking steps to achieve that future, now.



ipeace.com

Provigat

"Diabetes is a disease of people who can't control themselves". This is a strong stigma that still exists. However, with exactly the same lifestyle, some people develop diabetes, and others do not. It's due to their different physical constitution.

Our mission is to eliminate this solitary self-management with our cutting-edge remote glucose-monitoring technology and eventually eradicate the stigma of diabetes.



provigate.com

Dioseve Inc

Providing novel possibilities for all life.

Our revolutionary technology, DIO (Directly Induced Oocyte), is capable of producing an extremely large yield of fertilizable egg cells at a minimal cost in a fraction of the time.

We aim to create state-of-the-art solutions to a myriad of problems surrounding pregnancy, including infertility as a result of age and hereditary disorders.



dioseve.com

xFOREST Therapeutics

xFOREST Therapeutics aims to create a paradigm shift in drug discovery with its unique technological assets "FOREST", setting RNA structures as drug discovery targets. FOREST are technology platforms that integrate massively parallel biochemical analysis systems of 1,000~ species of RNA structures and in silico analysis pipelines. These comprehensive analyses include various RNA structures, regardless of their source: organ, species, or virus. As a result, the technologies have enabled the search for highly specific RNA-binders, empowering the rapid and efficient discovery of RNA-targeting drugs.



www.xforestx.com




Join **BioJent** Online Community of Entrepreneurs, Investors and Executives to:

01 Learn about biotech entrepreneurship, investment and technology commercialization

02 Access information about funding and professional development opportunities

03 Share and access job opportunities in the biotech communities

04 Apply for mentorship



OBJECTIVES

The program targets academia-origin founders, university technology transfer practitioners in biotech, Japanese biotechnology professors, and venture capital investors. The primary objectives include:

1. Identifying, training, and coaching the target audience through a workshop event.
2. Increasing investments in Japan-based biotech start-ups by connecting U.S. and Japanese biotech investors and venture capitalists.
3. Establishing a foundation for a Japan-based biotech investment pipeline and follow-up activities.
4. Catalyzing export business opportunities in Japan for American biotech startups.

IMPACT

The successful implementation of the program will create a U.S.-Japan community of biotech-focused founders, practitioners, and executives. It will also lead to increased investments in Japanese biotech start-ups by U.S. investors, improved entrepreneurship skills and international connectivity among Japanese researchers and start-up founders, and new market opportunities for U.S. companies targeting Japan's aging population.

PROGRAM ACTIVITIES

The one-year program consists of the following sets of activities:

1. Virtual Broadcast Series (VBS): A series of three virtual discussions will increase the visibility of investment opportunities in the Japanese biotech sector. Topics covered will include successful biotech ventures, raising capital, and building effective teams.
2. Biotech Ventures Workshop in Tokyo: A practical training and coaching event in Tokyo will bring together stakeholders for networking, fundraising pitching to investors, and technology and entrepreneurship skill-building. Selected Japanese biotech ventures will have the opportunity to pitch their ventures to a group of U.S. and Japanese investors and entrepreneurs.
3. Virtual 3-month Coaching: The top five ventures selected during the Tokyo Workshop will receive up to six hours of coaching over three months. The coaching will focus on supporting business strategy, development, and operations.

SUMMARY

BioJent entrepreneurship program is a vital step towards strengthening U.S.-Japan ties in the biotechnology sector, fostering global collaboration, and unleashing the full potential of Japan's innovative research. By empowering Japanese ventures with the right resources, the program will create a thriving ecosystem of biotech start-ups, benefitting both countries and making a lasting impact on the global biotechnology industry.

VIRTUAL BROADCASTS organised by OVIBEES VENTURES

UPCOMING BROADCAST



FROM LAB TO MARKET, COMMERCIALIZING UNIVERSITY TECHNOLOGIES

Virtual Broadcast webinar presented by the U.S. Embassy Tokyo, U.S. Consulate Fukuoka, JSNC and OviBees Ventures.



MEET THE SPEAKERS



Joe HADZIMA
President IP Vision, Senior Lecturer MIT Sloan School of Management



Rieko YAJIMA
Director Drug Discovery and Innovations, Stanford University, Spark Program



Errol ARKILIC
Chief Innovation Officer, UC Irvine, and Executive Director Beall Applied Innovation

MODERATOR



Ovidiu BUJOREAN
Founder & CEO OVIBEES Ventures

日本語通訳付き

JOIN US AND HAVE YOUR QUESTIONS ANSWERED HERE



FEBRUARY 9TH 2024
10:00 AM Tokyo Time
FEBRUARY 8TH 2024
9:00 PM Eastern Time





BUILDING SUCCESSFUL TEAMS IN BIOTECH VENTURES

Virtual Broadcast webinar presented by the U.S. Embassy Tokyo, U.S. Consulate Fukuoka, JSNC and OviBees Ventures.



MEET THE SPEAKERS



Ken HORNE
Managing Director, AN Venture Partners



David LUCCHINO
Co-founder/ CEO Frequency Therapeutics (Nasdaq: FREQ), former Chair MassBio



Sonny VU
Founder Alabaster, Founder, CEO, Chairman Misfit Wearables

MODERATOR



Ovidiu BUJOREAN
Founder & CEO OVIBEES Ventures

日本語通訳付き

JOIN US AND HAVE YOUR QUESTIONS ANSWERED HERE



MARCH 15TH 2024
10:00 AM Tokyo Time
MARCH 14TH 2024
9:00 PM Eastern Time



PAST BROADCAST



RAISING CAPITAL FOR A BIOTECH VENTURE

STEPS AND EXAMPLES FROM THE U.S. AND JAPAN

Virtual Broadcast webinar presented by the U.S. Embassy Tokyo, U.S. Consulate Fukuoka, JSNC and OviBees Ventures.



MEET THE SPEAKERS



Michael KOERIS
Chairman of the Board of Directors, Corvium
[in/mkoeris/](#)



Kirsten LEUTE
Partner, University relations, OUP Osage University Partners
[in/kirstenleute/](#)



Hiroki ASHIDA
Vicepresident, Eight Road Ventures
[in/hiroki-ashida-65844339](#)

MODERATOR



Ovidiu BUJOREAN
Founder & CEO OVIBEES Ventures
[in/bujorean](#)


日本語通訳付き

JOIN US AND HAVE YOUR QUESTIONS ANSWERED HERE



OCTOBER 27TH 2023
9:30 AM Tokyo Time
OCTOBER 26TH 2023
8:30 PM Eastern Time





bioJENT

 **FEBRUARY 9TH 2024**

Virtual Broadcast webinar presented by the U.S. Embassy Tokyo, U.S. Consulate Fukuoka, JSNC and OviBees Ventures.



FROM LAB TO MARKET, COMMERCIALIZING UNIVERSITY TECHNOLOGIES

MEET THE SPEAKERS



Joe HADZIMA

President IP Vision, Senior Lecturer MIT Sloan School of Management

Joseph Hadzima is a Senior Lecturer in the Martin Trust Center for MIT Entrepreneurship.

Hadzima works in the areas of entrepreneurship, startup phase companies, business plans, venture capital, corporate governance, and intellectual property strategy. He has been involved in the founding of more than 100 companies as a founder, investor, director, legal counsel, or employee, and has advised entrepreneurs, high-growth businesses, and venture capitalists.



Rieko YAJIMA

Director Drug Discovery and Innovations, Stanford University, Spark Program

Ph.D. life scientist with 8 years of experience in science policy and 2 years in human-centered design research. Focus on transdisciplinary and team science collaboration strategies and development.

Currently with the Center for Design Research at Stanford University investigating the role of design in scientific discovery and translational research, particularly in drug discovery R&D.



Errol ARKILIC

Chief Innovation Officer, UC Irvine, and Executive Director Beall Applied Innovation

Errol Arkilic, chief innovation officer at the University of California, Irvine (UCI), and executive director of Beall Applied Innovation, is a distinguished figure in academic-initiated technology commercialization. Before joining UCI in October 2021, he led M34 Capital, a venture firm specializing in academic spinouts. Arkilic is also renowned as the founder of the National Science Foundation Innovation Corps (I-Corps) program.



bioJENT



MARCH 15TH
2024

ovbees
VENTURES

BUILDING SUCCESSFUL TEAMS IN BIOTECH VENTURES

Virtual Broadcast webinar presented by the U.S. Embassy
Tokyo, U.S. Consulate Fukuoka, JSNC and OviBees Ventures.



MEET THE SPEAKERS



Ken HORNE

Managing Director, AN Venture Partners

Mr. Horne has over 20 years of experience in the life science industry as an executive, entrepreneur and investor. He currently chairs RDiscovery and leads Remiges Ventures's company-creation initiatives as CEO of Capacity Bio and Digestome Therapeutics. As an entrepreneur he co-founded or led Aline Aesthetics (acquired by Allergan), Symic Bio (acquired by Nordic Bio), and Teon Therapeutics.

Previously, he was a founding member of TauTona Group, an early-stage life science venture capital fund back by Stanford Management Company and other top LPs.



David LUCCHINO

Co-founder/ CEO Frequency Therapeutics (Nasdaq: FREQ), former Chair MassBio

David L. Lucchino has been a leader in the life sciences for more than two decades, as an executive, an entrepreneur, an investor and a policy and economic development leader. Most recently, he was the President and CEO of Frequency Therapeutics, Inc., a company he co-founded in 2014. Frequency was a regenerative medicine company, born out of the labs of the renown MIT Institute Professor Robert Langer, and focused on developing therapeutics to activate a person's innate potential to restore function within the body. The Company's pipeline included programs for sensorineural hearing loss and remyelination in Multiple Sclerosis.



Sonny VU

Founder Alabaster, Founder, CEO, Chairman Misfit Wearables

Founder of Misfit; Former President and CTO of Fossil Group, Connected Devices using fashion and design to make technology useful and beautiful. Co-founder of Elemental Machines (IoT, life science), Misfit (wearables), AgaMatrix (diabetes, digital health), FireSpout (natural language processing). Pre-startup life: worked at Microsoft Research in NLP under Kai-Fu Lee, worked on a PhD in Linguistics at MIT under Noam Chomsky, studied Math & Linguistics at UIUC. Love helping exceptional founders build companies based on scientific breakthroughs, especially in: materials science, semiconductors, food biotech.





OCTOBER 27TH
2023

Virtual Broadcast webinar presented by the U.S. Embassy
Tokyo, U.S. Consulate Fukuoka, JSNC and OviBees Ventures.



RAISING CAPITAL FOR A BIOTECH VENTURE

STEPS AND EXAMPLES FROM THE U.S. AND JAPAN

MEET THE SPEAKERS



Michael KOERIS

Chairman of the Board of Directors, Corvium

Dr. Michael Koeris serves as Professor of Bioprocessing and is a member of the Amgen Bioprocessing Center in the Department of Biological Engineering and Management. Prior to joining KGI in 2021, Koeris actively started, grew, and exited biotech startups, both as founder and senior leadership member and Board of Directors.

Koeris holds a PhD in Biomedical Engineering from Boston University and Masters and Bachelors degrees in Biochemistry and Biophysics from the Free University of Berlin, Germany.



Kirsten LEUTE

Partner, University relations, OUP Osage University Partners

Kirsten is an experienced technology transfer professional, spending 19 years in technology transfer at Stanford University and the German Cancer Research Center. Prior to joining OUP, she was Associate Director at Stanford's Office of Technology Licensing. Over her career at Stanford, she managed portfolios of inventions in most technology areas, but concentrated in biotechnology.

Kirsten has also been actively involved in technology transfer outside her daily work. She is a former two-time board member for the Association of University Technology Managers and speaks frequently on university technology transfer.




Hiroki ASHIDA

Vicepresident, Eight Road Ventures

Hiroki is a biotech investor at Eight Road Ventures, a global VC firm with more than \$10B in AUM and over 50 years of history. He helped establish their biotech investment practice in Japan seven years ago and covers all biotech and therapeutics deals. Hiroki works closely with their sister fund F-Prime Capital Partners in the US and other Eight Roads global teams around the world to invest both domestically and globally, leveraging the science and technologies from Japan. Hiroki aims to become a bridge between the global and Japanese markets.

Prior to joining Eight Roads, Hiroki worked as a management consultant at Accenture Strategy and holds a Ph.D. in computational biology from the University of Tokyo where he conducted research on epigenetics and ncRNAs.



Broadcast recording available here:



https://youtu.be/CDIBH8f5opY?si=C0q_1eWjHm-g81bU

Orrick - A Global Platform -

We focus on three sectors globally: **Technology & Innovation**, **Energy & Infrastructure** and **Financial Services**.

Orrick's **tech and life sciences practices** are continuing to experience extraordinary demand, as innovators and their financial backers continue making game-changing investments. We are partnering with our clients to leverage this momentum by helping them expand their businesses, protect their IP, and address risk.

An Integrated Approach to the Life Sciences Sector



500+ life sciences clients across all segments – biotech and pharma, digital health, research and laboratories, medical devices and diagnostics and tools.

Regardless of where our clients are in the corporate lifecycle, we offer them solutions scaled to their needs.

A top 5 global venture capital practice and a powerful network of resources for innovative entrepreneurs and private companies.

A sterling record of **successful exits** through sale, IPO or SPAC transactions.

IP licensing expertise, delivered through the practical, business-minded advice from a team that draws from decades of government, private, and industry experience.

Patent strategy and prosecution support from a team that knows the science (and has the PhDs to prove it).

Regulatory, compliance, and public policy advice to mitigate risk from a team that is regularly on the front lines representing clients through internal and government investigations.

Litigation representation from a team that has navigated some of the biggest and messiest trade secret, patent, securities, mass torts, and class action employment disputes on record on behalf of some of the leading life sciences companies in the world.



www.ovibe'es.com

OviBees Ventures, Build Local. Reach Global.

OviBees Ventures, LLC is a forward-looking venture accelerator with a mission to globalize the most promising early-stage tech startups. We unleash the potential of start-ups in emerging and developed markets through public-private partnerships, comprehensive venture support and strategic partner introductions. Our cross-border expertise and business networks provide us with a leading edge to drive deep market transformations through an entrepreneurs centric approach.

OviBees Ventures designs and deploys a wide range of startup ecosystem activities from venture ideation caravans to startup bootcamps and nationwide startup competitions. Our in-country activities are empowered, and scaled through our proprietary online and mobile platforms which are adapted and customized for the specific countries and industries of focus. We know how to build hope and by building hope we build communities of like-minded trailblazers.



Ovidiu Bujorean

Ovidiu Bujorean, a MIT and Harvard alumni and scholar of the Joint Japan/World Bank Graduate Scholarship Program, the founder of OviBees Ventures, is a leader in designing and implementing platforms that encourage technology-based entrepreneurship at country and regional levels. His previous work with The GIST Network, the U.S. Department of State flagship entrepreneurship program, a global enterprise building entrepreneurial ecosystems across 135 countries, showcased his dedication to fostering entrepreneurship on a global scale.